GLP-1 Pill Showdown; $35 Insulin Cap Success; Preterm Births Tied to Plastics

Novo Nordisk said its semaglutide (Wegovy) pill outperformed recently approved orforglipron (Foundayo) in weight loss and tolerability in an indirect comparison using clinical trial data, and the company launched multi-month subscriptions for its semaglutide products for obesity.

There is growing acceptance that a male version of polycystic ovary syndrome exists, STAT reported.

A time series analysis showed that Medicare’s $35 out-of-pocket insulin cap was linked to improved access, reduced blood glucose levels, and a small rise in severe hypoglycemia rates among beneficiaries with type 2 diabetes. (JAMA Internal Medicine)

Amgen said that 77% of patients with moderate-to-severe thyroid eye disease achieved a significant proptosis response with subcutaneous teprotumumab (Tepezza). The treatment currently is approved only as an IV infusion.

Meanwhile, Immunovant’s investigational batoclimab failed in two late-stage trials for the same condition.

The FDA approved a 5-month dosing interval for aflibercept (Eylea HD) to treat diabetic macular edema and wet age-related macular degeneration, Regeneron announced.

Plastic-associated chemicals were linked to an estimated 1.93 million preterm births globally in 2018, with the highest absolute burden in the Middle East and South Asia. (eClinicalMedicine)

Survey data showed that walking was the most prevalent leisure-time physical activity among U.S. adults, but many walkers failed to meet physical activity guidelines. (PLOS One)

The World Obesity Federation issued a position statement warning that systemic barriers to exercise have stalled global progress in managing obesity. (Obesity Reviews)

An analysis of 6.86 billion Taco Bell transactions found that sugary drink taxes had no significant impact on beverage calories per transaction. (PLOS Medicine)

Please enable JavaScript to view the comments powered by Disqus.